Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewReported as active at the glycine site of the NMDA receptor but having little action at AMPA or kainate receptors.
M. Wt | 231.04 |
Storage | Store at RT |
CAS Number | 25983-13-5 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Kleckner and Dingledine (1989) Selectivity of quinoxalines and kynurenines as antagonists of the glycine site on N-MthD.-aspartate receptors. Mol.Pharmacol. 36 430 PMID: 2550776
Ogita et al (1990) 6,7-dichloroquinoxaline-2,3-dione is a competitive antagonist specific to the strychnine-insensitive [3H]glycine binding sites on the N-MthD.-aspartate receptor complex. J.Neurochem 54 699 PMID: 1967633
Yoneda and Ogita (1989) Abolition of the NMDA-mediated responses by a specific glycine antagonist, 6,7-dichloroquinoxaline-2,3-dione (DCQX). Biochem.Biophys.Res.Commun. 164 841 PMID: 2554902
Keywords: DCQX, DCQX supplier, NMDA, Receptors, 0196, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for DCQX.
There are currently no reviews for this product. Be the first to review DCQX and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.